Evidence map›Paper›PMID 30574185›Full record

ReviewJournal of biological engineering2018

Delivery systems of CRISPR/Cas9-based cancer gene therapy.

Alessio Biagioni, Anna Laurenzana, Francesca Margheri, Anastasia Chillà, Gabriella Fibbi, Mario Del Rosso

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of biological engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Genome Editing and Fatty Liver.Advances in experimental medicine and biology · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Hypoxia-sensitive miRNA regulationFrontiers in cell and developmental biology · 2022
    Article
  15. Review
  16. EditingInternational journal of molecular sciences · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Alessio BiagioniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.ORCID 0000-0002-6193-7417
Anna LaurenzanaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.
Francesca MargheriDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.
Anastasia ChillàDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.
Gabriella FibbiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.
Mario Del RossoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale G.B. Morgagni 50 -, 50134 Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) is today one of the most reliable method for gene-editing, supporting previous gene therapies technologies such as TALEN, Meganucleases and ZFNs. There is a growing up number of manuscripts reporting several successful gene-edited cancer cell lines, but the real challenge is to translate this technique to the clinical practice. While treatments for diseases based on a single gene mutation is closer, being possible to target and repair the mutant allele in a selective way generating specific guide RNAs (gRNAs), many steps need to be done to apply CRISPR to face cancer. In this review, we want to give a general overview to the recent advancements in the delivery systems of the CRISPR/Cas9 machinery in cancer therapy.

Indexed as

CancerCRISPRDelivery systemsGene-editingGene therapy

Identifiers

PMID30574185
PMCPMC6299643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.